Although a similar pattern was observed for IL-18 with the SVR rate beginning at 61% in Q1 and falling to 44% in Q4, this did not reach statistical significance ( Figure 4F ).
← all excerpts
The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir.
1
—
—